
This story is part of STAT’s quarterly series Something Ventured, which looks at early-stage startups. You can read the earlier stories in the series here.
Every quarter, the CEO of a public biotech company can expect to spend an hour or two on the phone, describing her company’s progress to shareholders and reporters and answering questions from analysts.